The Rosen Law Firm was sole Lead Counsel in this class action in the U.S. District Court for the Central District of California. The complaint alleged violations of §§10b and 20(a) of the Securities Exchange Act arising out of the Company’s issuance of materially false statements regarding the clinical testing of one its products. The parties settled this action for $3.4 million in cash.
